Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

US Tech Dip Healthy? Expert Predicts S&P 7000, Sees Bright Future for Indian Stocks!

Economy

|

Updated on 10 Nov 2025, 06:53 am

Whalesbook Logo

Reviewed By

Satyam Jha | Whalesbook News Team

Short Description:

Ed Yardeni, President at Yardeni Research, views the recent pullback in high-flying US tech and AI stocks as a healthy correction, not a sign of a market meltdown. He maintains his optimistic outlook for US equities, targeting the S&P 500 at 7,000, and sees potential catalysts in resolved government shutdowns. Yardeni also expressed a positive view on Indian equities, aligning with Goldman Sachs' 'overweight' upgrade, calling the recent flat-to-down performance a healthy consolidation. He highlighted the strategic shift of production away from China into countries like India as a significant long-term positive for India.
US Tech Dip Healthy? Expert Predicts S&P 7000, Sees Bright Future for Indian Stocks!

▶

Detailed Coverage:

Ed Yardeni, President at Yardeni Research, believes the recent sell-off in prominent US technology and artificial intelligence stocks is a healthy pullback, reassuring investors that a market meltdown similar to 1999-2000 is unlikely, especially since many are already anticipating it. He remains optimistic about the broader US equity market, reiterating his forecast for the S&P 500 to reach 7,000 by year-end, identifying a potential resolution to the government shutdown as a positive catalyst.

Yardeni downplayed concerns over job cuts, attributing them mainly to productivity gains in the technology sector and the shift towards robotics in warehousing, rather than a fundamental demand weakness. He anticipates displaced tech workers will find new roles swiftly.

On US politics, he expects continuity in core Trump administration policies but a shift in rhetoric, with Republicans focusing more on affordability, lower energy prices, and potentially reduced food costs. Regarding existing tariffs, he suggested the administration would likely claim success regardless of legal challenges, as they served their purpose in trade deal renegotiations.

Turning to India, Yardeni echoed Goldman Sachs' 'overweight' upgrade for Indian equities. He described the recent period of flat-to-down market performance in India as a "healthy development" that allows valuations to realign with earnings growth after years of strong returns. He concluded that India's outlook is "quite good," especially with the resolution of global trade uncertainties and the ongoing strategic shift of production away from China into nations like India, which presents a significant long-term tailwind.

Impact: This news has a direct impact on the Indian stock market by influencing investor sentiment and strategy concerning Indian equities, supported by expert opinions and institutional upgrades. It also impacts US equities by providing a bullish outlook and context for recent volatility. Global business is affected by discussions on trade policy and production shifts.

Terms: * **Sell-off**: A rapid and significant decline in stock prices. * **High-flying stocks**: Stocks of companies that have experienced rapid and substantial price increases, often in growth sectors. * **Artificial intelligence (AI) stocks**: Stocks of companies involved in the development, manufacturing, or application of artificial intelligence technologies. * **Market meltdown**: A severe and sudden collapse of stock market prices. * **S&P 500**: A stock market index representing the performance of 500 of the largest publicly traded companies in the United States. * **Equities**: Another term for stocks or shares, representing ownership in a company. * **Bull phase/Bull market**: A period when stock prices are generally rising or are expected to rise. * **Catalyst**: An event or factor that causes a significant change or action, such as a rise in stock prices. * **Government shutdown**: A situation where non-essential government operations cease due to a failure by lawmakers to pass appropriation bills. * **Productivity gains**: Increases in the efficiency of production, meaning more output is produced with the same or fewer inputs. * **Robotics and automation**: The use of robots and automated systems to perform tasks previously done by humans. * **Tariffs**: Taxes imposed on imported goods. * **Unconstitutional**: Not in accordance with the principles of a constitution. * **Trade deals**: Agreements between countries concerning the exchange of goods and services. * **Indian equities**: Stocks or shares of companies listed on Indian stock exchanges. * **Overweight**: An investment rating indicating that a particular asset or sector is expected to perform better than the overall market. * **Valuations**: The process of determining the current worth of an asset or company. * **Earnings growth**: An increase in a company's profits over time. * **Tailwind**: A factor that promotes or supports progress or success.


Healthcare/Biotech Sector

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?


Chemicals Sector

Clean Science Stock Under Pressure: ICICI Securities Cuts Target Price, Downgrades to HOLD – Read the Full Analysis!

Clean Science Stock Under Pressure: ICICI Securities Cuts Target Price, Downgrades to HOLD – Read the Full Analysis!

Clean Science Stock Under Pressure: ICICI Securities Cuts Target Price, Downgrades to HOLD – Read the Full Analysis!

Clean Science Stock Under Pressure: ICICI Securities Cuts Target Price, Downgrades to HOLD – Read the Full Analysis!